Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Not yet recruiting 3Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 75Colorectal Neoplasms 28Breast Neoplasms 23Esophageal Neoplasms 20Pancreatic Neoplasms 13Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Rectal Neoplasms 9Ovarian Neoplasms 8Endometrial Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5HER2-positive Gastric Cancer 5Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Adenocarcinoma 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Bile Duct Neoplasms 3Vulvar Neoplasms 2

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Trastuzumab × Gastrointestinal × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
153 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05311189 2022-04-05

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Shanghai Zhongshan Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡